NEWS: Worldwide best-validated anti-PSA antibody published now - validated on 21.000 tissues.

test our



Clone TG1 is simply the best anti-TIGIT antibody available so far – as proven by beta-tests from different labs.


Clone KK3 is highly efficient in detection of CD73-adenosine in normal and tumor FFPE tissue.


Clone TG8 has been optimized for optimal signal-to-noise contrast and validated for detection of CD8+ TILs in FFPE tissue.


Clone HAM18 has been tested on >20.000 tissues and is the best characterized anti-PSA antibody.


Coming soon – This unique clone displays unparalleled quality for CD112R detection in tumors & normal tissues.


Coming soon – The new clone has been validated on hundreds of tissues and will be published soon.


Coming soon – This clone has been validated extensively on a high range of tissues to document unparalleled quality.


Clone JAP16 is outstanding and superior to competitors as proven by beta-tests from different labs.

We are always happy to discuss your needs!



ONCOdianova is an antibody manufacturing network. The purpose is to manufacture excellent antibodies with optimized signal-to-noise ratio. Such optimized antibodies are especially needed in multicolor fluorescence based immunohistochemistry if many different antibodies are simultaneously analyzed. The mission of ONCOdianova is to develop a portfolio of “best in class antibodies” for proteins that are potentially relevant for triggering treatment decisions or for diagnostic pathology.


Our idea is to integrate immunohistochemistry as early as possible in the hybridoma screening procedure and thereby expand the classical ELISA screen by histopathological expertise at an early stage of FFPE antibody development.


We use our strong network for histopathological validation of new targets in human tissues. This expands our expertise to develop new test systems for novel targets. For cancer immunology targets we put a focus on tumor infiltrating lymphocytes.


Multiplex Assay technology develops fast and depends on the availability of reliable antibody reagents. Our vision is to provide the best cancer immunology marker antibodies for combined use to improve the understanding of patient subpopulations.


Our objective is to potentially develop multiple clones for the same target by approaching one target at diverse immunogenic sites. We are able to reference mapped epitopes and open for beta testing opportunities with pharmaceutical partners.